Treatment of Endotoxemia

[1]  N. White,et al.  Prevention of ischaemia-induced small intestinal adhesions in foals. , 2010, Equine veterinary journal.

[2]  M. Barton,et al.  Polymyxin B protects horses against induced endotoxaemia in vivo. , 2010, Equine veterinary journal.

[3]  P. Rossitto,et al.  Efficacy of an Escherichia coli J-5 mutant strain bacterin in the protection of calves from endotoxin disease caused by subcutaneous challenge with endotoxins from Escherichia coli. , 2004, Vaccine.

[4]  Steven B. Johnson,et al.  Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.

[5]  P. Toutain,et al.  Pharmacokinetics of meloxicam in plasma and urine of horses. , 2004, American journal of veterinary research.

[6]  A. Blikslager,et al.  Effects of ischemia and the cyclooxygenase inhibitor flunixin on in vitro passage of lipopolysaccharide across equine jejunum. , 2004, American journal of veterinary research.

[7]  A. Blikslager,et al.  Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia. , 2004, American journal of veterinary research.

[8]  J. Snyder,et al.  Survey of prokinetic use in horses with gastrointestinal injury. , 2004, Veterinary surgery : VS.

[9]  S. Opal,et al.  Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. , 2003, Vaccine.

[10]  L. Hellebrekers,et al.  Effects of intravenous lidocaine on isoflurane concentration, physiological parameters, metabolic parameters and stress-related hormones in horses undergoing surgery. , 2003, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

[11]  M. Vandenplas,et al.  Lipopolysaccharide from Rhodobacter sphaeroides is an agonist in equine cells , 2003, Journal of endotoxin research.

[12]  W. Geerts,et al.  Low-dose heparin for severe sepsis. , 2002, The New England journal of medicine.

[13]  D. Annane,et al.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. , 2002, JAMA.

[14]  H. Wunderli-Allenspach,et al.  Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horses. , 2002, American journal of veterinary research.

[15]  S. Opal,et al.  Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. , 2001, The Journal of infectious diseases.

[16]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[17]  G. Mchedlishvili,et al.  Blood flow structure related to red cell flow: determinant of blood fluidity in narrow microvessels. , 2001, The Japanese journal of physiology.

[18]  M. Barton,et al.  Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro. , 2000, Shock.

[19]  B. Monks,et al.  Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. , 2000, The Journal of clinical investigation.

[20]  M. Papich,et al.  Pharmacokinetics of ibuprofen after intravenous and oral administration and assessment of safety of administration to healthy foals. , 1999, American journal of veterinary research.

[21]  M. Yen,et al.  Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia. , 1999, European journal of pharmacology.

[22]  J. Wittes,et al.  Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Seahorn,et al.  Renal medullary rim sign in 2 adult quarter horses. , 1998, The Canadian veterinary journal = La revue veterinaire canadienne.

[24]  D. Weiss,et al.  The sepsis-coagulant axis: a review. , 1998, Journal of veterinary internal medicine.

[25]  T. Doherty,et al.  Effect of intravenous lidocaine on halothane minimum alveolar concentration in ponies. , 1998, Equine veterinary journal.

[26]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[27]  M. Barton,et al.  The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. , 1997, Journal of veterinary pharmacology and therapeutics.

[28]  R. Rosenberg.  Biochemistry and pharmacology of low molecular weight heparin. , 1997, Seminars in hematology.

[29]  E. Martin,et al.  Influence of Lidocaine on Endotoxin-induced Leukocyte-Endothelial Cell Adhesion and Macromolecular Leakage in Vivo , 1997, Anesthesiology.

[30]  G. Bernard,et al.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. , 1997, The New England journal of medicine.

[31]  J. Traub-Dargatz,et al.  Survey of diplomates of the American College of Veterinary Internal Medicine and the American College of Veterinary Surgeons regarding clinical aspects and treatment of endotoxemia in horses. , 1997, Journal of the American Veterinary Medical Association.

[32]  M. Vaara.  Lipid A--Target for Antibacterial Drugs , 1996, Science.

[33]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[34]  Greg D. BonenClark,et al.  Effect of vaccination of ponies with A4 anti-idiotypic antibody on serum idiotype (1C9) and antilipid A concentration. , 1996, American journal of veterinary research.

[35]  R. MacKay,et al.  Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of miniature horses given endotoxin. , 1995, American journal of veterinary research.

[36]  M. Monreal,et al.  Comparison of the effects of low-molecular-weight and unfractioned heparin in horses. , 1995, American journal of veterinary research.

[37]  A. Seawright,et al.  Kinetics, dose response, tachyphylaxis and cross-tachyphylaxis of vascular leakage induced by endotoxin, zymosan-activated plasma and platelet-activating factor in the horse. , 1995, Journal of veterinary pharmacology and therapeutics.

[38]  J. Snyder,et al.  Microvascular permeability and endothelial cell morphology associated with low-flow ischemia/reperfusion injury in the equine jejunum. , 1995, American journal of veterinary research.

[39]  A. Robidoux,et al.  E5531, a pure endotoxin antagonist of high potency. , 1995, Science.

[40]  D. Mollitt,et al.  Effect of sepsis on erythrocyte intracellular calcium homeostasis. , 1995, Critical care medicine.

[41]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[42]  N. Cohen,et al.  Prevalence and factors associated with development of laminitis in horses with duodenitis/proximal jejunitis: 33 cases (1985-1991). , 1994, Journal of the American Veterinary Medical Association.

[43]  D. Morrison,et al.  Lipopolysaccharide (LPS) binding to 73-kDa and 38-kDa surface proteins on lymphoreticular cells: preferential inhibition of LPS binding to the former by Rhodopseudomonas sphaeroides lipid A. , 1993, Immunology letters.

[44]  M. Crisman,et al.  Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. , 1993, Journal of veterinary pharmacology and therapeutics.

[45]  J. Moore,et al.  Endotoxemia and septicemia in horses: experimental and clinical correlates. , 1992, Journal of the American Veterinary Medical Association.

[46]  Robert J. MacKay,et al.  Anti-equine tumor necrosis factor (TNF) activity of antisera raised against human TNF-alpha and peptide segments of human TNF-alpha. , 1992, American journal of veterinary research.

[47]  J. Koziol,et al.  Tumour necrosis factor alpha antibody protects against lethal meningococcaemia , 1992, Molecular microbiology.

[48]  M. Kawamura,et al.  Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. , 1992, The Journal of pharmacology and experimental therapeutics.

[49]  J. Potempa,et al.  Antithrombin III activity in horses with colic: an analysis of 46 cases. , 1991, Equine veterinary journal.

[50]  D. D. Morris,et al.  Endotoxemia in horses. A review of cellular and humoral mediators involved in its pathogenesis. , 1991, Journal of veterinary internal medicine.

[51]  Henry Mm,et al.  Influence of an omega-3 fatty acid-enriched ration on in vivo responses of horses to endotoxin. , 1991 .

[52]  E. Hardie,et al.  Endotoxic shock. Part II: A review of treatment. , 1990, Journal of veterinary internal medicine.

[53]  L F Karcher,et al.  Right dorsal colitis. , 1990, Journal of veterinary internal medicine.

[54]  E. Hardie,et al.  Endotoxic shock. Part I: A review of causes. , 1990, Journal of veterinary internal medicine.

[55]  Osweiler Gd,et al.  Effects of polymyxin B on selected features of equine carbohydrate overload. , 1989 .

[56]  J. Holaday,et al.  Calcium administration increases the mortality of endotoxic shock in rats. , 1989, Critical care medicine.

[57]  Moore Jn,et al.  Evaluation of heparin for prophylaxis of equine laminitis: 71 cases (1980-1986). , 1989 .

[58]  M. Garg,et al.  Omega-3 fatty acids increase the arachidonic acid content of liver cholesterol ester and plasma triacylglycerol fractions in the rat. , 1989, The Biochemical journal.

[59]  J. N. King,et al.  Biphasic disruption of fasting equine gut motility by dopamine--a preliminary study. , 1988, Journal of veterinary pharmacology and therapeutics.

[60]  J. Weil,et al.  Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. , 1988, The American review of respiratory disease.

[61]  E. Gerring,et al.  Detection of endotoxin in cases of equine colic , 1988, Veterinary Record.

[62]  H. Erb,et al.  Prevention of intraabdominal adhesions in ponies by low-dose heparin therapy. , 1987, Veterinary surgery : VS.

[63]  G. Hardee,et al.  Low dose flunixin meglumine: effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses. , 1987, Equine veterinary journal.

[64]  N. White,et al.  Factors for prognostic use in equine obstructive small intestinal disease. , 1986, Journal of the American Veterinary Medical Association.

[65]  D. D. Morris,et al.  Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide. , 1986, American journal of veterinary research.

[66]  I. Johnstone,et al.  Hemostatic abnormalities in equine colic. , 1986, American journal of veterinary research.

[67]  J. McCutchan,et al.  PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID , 1985, The Lancet.

[68]  C. Hillidge.  The case for dimethyl sulphoxide (DMSO) in equine practice. , 1985, Equine veterinary journal.

[69]  R. Hancock,et al.  Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species , 1984, Infection and immunity.

[70]  D. Strandness,et al.  Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. , 1982, American heart journal.

[71]  G. Bottoms,et al.  Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. , 1981, American journal of veterinary research.

[72]  B. Buchanan,et al.  Bioassay of endotoxin clearance in vivo and by perfused rat liver. , 1976, The American journal of physiology.

[73]  K. Corley.  Chapter 17 – Fluid therapy , 2004 .

[74]  S. Weisbrode,et al.  Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants. , 2001, American journal of veterinary research.

[75]  M. Barton,et al.  Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. , 2001, American journal of veterinary research.

[76]  A. Vannucchi,et al.  Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. , 1996 .

[77]  B. R. Moore,et al.  Heparin: a review of its pharmacology and therapeutic use in horses. , 1994, Journal of veterinary internal medicine.

[78]  N. Cohen,et al.  Disseminated intravascular coagulation associated with colic in 23 horses (1984-1989). , 1992, Journal of veterinary internal medicine.

[79]  G. Hardee,et al.  Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. , 1986, American journal of veterinary research.

[80]  G. Bottoms,et al.  Endotoxin-induced change in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: effects of flunixin meglumine. , 1982, American journal of veterinary research.

[81]  Burrows Ge.  Therapeutic effect of phenylbutazone on experimental acute Escherichia coli endotoxemia in ponies. , 1981, American journal of veterinary research.

[82]  E. D. Jacobson,et al.  Effects of Calcium and Its Antagonists on the Canine Mesenteric Circulation Calcium Ions (ca , 2022 .